This appears to be secondary to a reduction in albumin that may be secondary to a number of factors, including operative management, adjuvant oncological therapies or tumour progression, a pattern recognized in previous studies within specific tumour types (McMillan et al, 2003; Jamieson et al, 2005). The gene discussed is ALB; the disease is neoplasm.